MedRx Co., Ltd (4586.T)
JPY 84.0
(-3.45%)
JPY 84.0
(-3.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -884.51 Million JPY | 15.57% |
| 2022 | -1.05 Billion JPY | -4.81% |
| 2021 | -996.66 Million JPY | 8.36% |
| 2020 | -1.05 Billion JPY | 31.89% |
| 2019 | -1.58 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 51.5 Million JPY | 124.56% |
| 2024 Q1 | -176.07 Million JPY | 34.12% |
| 2023 Q4 | -251.32 Million JPY | -30.5% |
| 2023 FY | - JPY | 15.57% |
| 2023 Q3 | -192.58 Million JPY | -4.86% |
| 2023 Q2 | -183.66 Million JPY | 37.74% |
| 2023 Q1 | -294.96 Million JPY | 39.47% |
| 2022 Q4 | -487.33 Million JPY | -106.41% |
| 2022 FY | - JPY | -4.81% |
| 2022 Q3 | -236.09 Million JPY | 0.0% |
| 2021 FY | - JPY | 8.36% |
| 2020 FY | - JPY | 31.89% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 114.691% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 100.101% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 99.685% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 100.474% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | 254.914% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 102.437% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 107.211% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 100.858% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | 168.408% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 104.823% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 109.858% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | 124.101% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | 163.045% |
| Tsumura & Co. | 30.77 Billion JPY | 102.874% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 104.725% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 116.781% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 102.489% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 112.853% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 105.048% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 108.591% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 76.413% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 111.711% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | -23.882% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 115.977% |
| Solasia Pharma K.K. | -635 Million JPY | -39.294% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 62.74% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 109.653% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 102.399% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | -64.32% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 103.422% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 117.338% |